Physician profile
Gary Moskowitz
NPI 1407852189
$5,606.69
in general payments reported to CMS, 2019-2025
34 companies · $1,115 in 2025
The $1,115 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $594 · 2021: $724 · 2022: $856 · 2023: $1,038 · 2024: $1,103 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,255.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,421.46 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,259.38 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $578.16 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $206.67 | 2019-2025 | Nucala, Trelegy Ellipta |
| Pfizer INC. | $189.82 | 2020-2025 | |
| Lilly USA, LLC | $173.48 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $150.76 | 2019-2023 | Belsomra |
| Amgen INC. | $115.03 | 2021 | |
| Eisai INC. | $114.72 | 2020-2021 | |
| Allergan, INC. | $111.91 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.16 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.05 | 2020-2025 | Jascayd, Jardiance, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $104.61 | 2023-2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $86.35 | 2024 | Voquezna |
| Exact Sciences Corporation | $82.12 | 2024-2025 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $79.74 | 2024-2025 | Ibsrela |
| Braintree Laboratories, INC. | $73.85 | 2019-2024 | Sutab, Suflave |
| Verona Pharma, INC. | $63.46 | 2025 | Ohtuvayre |
| Janssen Biotech, INC. | $62.74 | 2025 | Tremfya |
| Amarin Pharma, INC. | $57.58 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.03 | 2022 | |
| Novartis Pharmaceuticals Corporation | $54.58 | 2019-2025 | |
| Evoke Pharma, INC. | $52.25 | 2024-2025 | |
| Redhill Biopharma INC. | $50.60 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $44.19 | 2024-2025 | Gvoke Hypopen |
| Lundbeck LLC | $40.96 | 2024 | Rexulti |
| Genentech USA, INC. | $39.77 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $34.46 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.99 | 2024 | Eohilia |
| Currax Pharmaceuticals LLC | $15.50 | 2020 | |
| Daiichi Sankyo INC. | $14.24 | 2020 | |
| Ironwood Pharmaceuticals, INC | $13.26 | 2022 | |
| Esperion Therapeutics, INC. | $12.62 | 2021 | |
| Hikma Pharmaceuticals USA | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Moskowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.